Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa–based methods overestimate antithrombin activity in some patients?
- 15 March 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (6) , 2271-2272
- https://doi.org/10.1182/blood-2001-11-0047
Abstract
Antithrombin is a single-chain glycoprotein of 432 amino acids. It is the most important endogenous coagulation inhibitor and inhibits several coagulation factors: IXa, Xa, XIa, XIIa, and thrombin (of which the inhibition of thrombin probably is the most important). In 1992 Blajchman et al[1][1]Keywords
This publication has 4 references indexed in Scilit:
- Evaluation of a new immunoturbidimetric test (Liatest® antithrombin III) for determination of antithrombin antigenClinical and Laboratory Haematology, 2001
- Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivityBlood, 1992
- Bovine or human thrombin in amidolytic at III assays. Influence of heparin cofactor IIThrombosis Research, 1986
- Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH)Thrombosis Research, 1977